Supplementary Information

Figure S1. HRESIMS of lobophorin H (**1**)……...…2
Figure S2. ^{1}H NMR (600 MHz, $CDCl_3$) spectrum of lobophorin H (**1**)…….2
Figure S3. ^{13}C NMR (150 MHz, $CDCl_3$) spectrum of lobophorin H (**1**)……3
Figure S4. HSQC of lobophorin H (**1**)……..…3
Figure S5. HMBC of lobophorin H (**1**)……..4
Figure S6. ^{1}H-^{1}H COSY of lobophorin H (**1**)…….4
Figure S7. NOESY of lobophorin H (**1**)……..5
Figure S8. HRESIMS of lobophorin I (**2**)……5
Figure S9. ^{1}H NMR (600 MHz, $CDCl_3$) spectrum of lobophorin I (**2**)……6
Figure S10. ^{13}C NMR (150 MHz, $CDCl_3$) spectrum of lobophorin I (**2**)……6
Figure S11. HSQC of lobophorin I (**2**)…….7
Figure S12. HMBC of lobophorin I (**2**)……7
Figure S13. ^{1}H-^{1}H COSY of lobophorin I (**2**)……..…….8
Figure S14. HRESIMS of *O*-β-kijanosyl-(1→17)-kijanolide (**3**)……...….8
Figure S15. ^{1}H NMR (600 MHz, $CDCl_3$) spectrum of *O*-β-kijanosyl-(1→17)-kijanolide (**3**)….9
Figure S16. ^{13}C NMR (150 MHz, $CDCl_3$) spectrum of *O*-β-kijanosyl-(1→17)-kijanolide (**3**)…9
Figure S17. HRESIMS of lobophorin B (**4**)……..……10
Figure S18. ^{1}H NMR (600 MHz, $CDCl_3$) spectrum of lobophorin B (**4**)…….….…….10
Figure S19. ^{13}C NMR (150 MHz, $CDCl_3$) spectrum of lobophorin B (**4**)…….11
Figure S20. HRESIMS of lobophorin F (**5**)……11
Figure S21. ^{1}H NMR (600 MHz, $CDCl_3$) spectrum of lobophorin F (**5**)……12

Figure S1. HRESIMS of lobophorin H (**1**).



Figure S2. ^{1}H NMR (600 MHz, $CDCl_3$) spectrum of lobophorin H (**1**).



Figure S3. ^{13}C NMR (150 MHz, $CDCl_3$) spectrum of lobophorin H (**1**).



Figure S4. HSQC of lobophorin H (**1**).



Figure S5. HMBC of lobophorin H (**1**).



Figure S6. ^{1}H-^{1}H COSY of lobophorin H (**1**).



Figure S7. NOESY of lobophorin H (**1**).



Figure S8. HRESIMS of lobophorin I (**2**).



Figure S9. ^{1}H NMR (600 MHz, $CDCl_3$) spectrum of lobophorin I (**2**).



Figure S10. ^{13}C NMR (150 MHz, $CDCl_3$) spectrum of lobophorin I (**2**).



Figure S11. HSQC of lobophorin I (**2**).



Figure S12. HMBC of lobophorin I (**2**).



Figure S13. ^{1}H-^{1}H COSY of lobophorin I (**2**).



Figure S14. HRESIMS of *O*-β-kijanosyl-(1→17)-kijanolide (**3**).

Method	LIU 250-500 NEG.m			Operator	Bruker Customer
Sample Name	12A35-4D-NEG			Instrument / Ser#	micrOTOF-Q 125
Comment					

Acquisition Parameter

Source Type	ESI	Ion Polarity	Negative	Set Nebulizer	0.3 Bar
Focus	Not active	Set Capillary	3800 V	Set Dry Heater	180 °C
Scan Begin	50 m/z	Set End Plate Offset	-500 V	Set Dry Gas	4.0 l/min
Scan End	3000 m/z	Set Collision Cell RF	450.0 Vpp	Set Divert Valve	Source

Generate Molecular Formula Parameter

Formula, min.			
Formula, max.			
Measured m/z		Tolerance	Charge
Check Valence		Minimum	Maximum
Nirogen Rule		Electron Configuration	
Filter H/C Ratio		Minimum	Maximum
Estimate Carbon			



Figure S15. ^{1}H NMR (600 MHz, $CDCl_3$) spectrum of *O*-β-kijanosyl-(1→17)-kijanolide (**3**).



Figure S16. ^{13}C NMR (150 MHz, $CDCl_3$) spectrum of *O*-β-kijanosyl-(1→17)-kijanolide (**3**).



Figure S17. HRESIMS of lobophorin B (**4**).



Figure S18. ^{1}H NMR (600 MHz, $CDCl_3$) spectrum of lobophorin B (**4**).



Figure S19. ^{13}C NMR (150 MHz, $CDCl_3$) spectrum of lobophorin B (**4**).



Figure S20. HRESIMS of lobophorin F (**5**).



Figure S21. ^{1}H NMR (600 MHz, $CDCl_3$) spectrum of lobophorin F (**5**).